R

Roche

Global pharmaceuticals and diagnostics company

Chief of Staff - GPS Oncology, Hematology

Full-TimeDeadline 9/28/26
No salary listed
Expert
Bachelor's, Master's
South San Francisco, CA, USA
Remote

About the job

Requirements
  • At least 10 years of work experience in pharmaceutical, biotech, or another highly regulated industry.
  • Experience working in a global environment and leading complex, high-impact projects from design through execution in a matrix setting.
  • Experience leading large-scale initiatives, projects, or programs in a matrix organization.
  • Extensive experience organizing, leading, driving, and implementing multiple complex initiatives.
  • Strong prioritization skills for tasks, meetings, and initiatives.
  • Experience collaborating with senior leaders, building a broad network beyond Global Product Strategy, and representing the organization's voice across multiple forums.
  • Excellent verbal and written English communication skills.
  • Experience facilitating meetings and setting agendas to support efficient and effective decision-making.
  • Strong presentation creation skills, including presenting complex content clearly and concisely to drive focused decision-making.
  • Master's Degree.
Responsibilities
  • Collaborate with Therapeutic Area heads to define strategic priorities, strategic review cycles, and operational plans.
  • Lead implementation of strategic initiatives and ensure alignment with overall business objectives.
  • Prepare comprehensive reports, presentations such as quarterly business reviews, and communication materials for senior leadership and Global Product Strategy Leadership Team audiences.
  • Engage internal and external stakeholders to foster relationships and drive strategic collaborations.
  • Serve as the central point of contact for the Therapeutic Area Leadership Team.
  • Cascade decisions made by the Therapeutic Area Leadership Team to appropriate channels, follow up on execution, communicate across Therapeutic Areas, and contribute to building and enabling Therapeutic Area and Global Product Strategy culture.
  • Ensure smooth day-to-day operations of the Therapeutic Area.
  • Streamline processes and procedures to improve efficiency and effectiveness.
  • Facilitate effective decision-making and execution of key strategies, including orchestrating key discussion and decision meetings, quarterly business reviews, and intersections with disease biology and biomarker teams.
  • Define the Therapeutic Area Leadership Team meeting cadence, agenda, and logistics in collaboration with Operations Partners.
  • Partner with functional business partners to implement corporate planning processes and align targeted goals and outcomes.
  • Coach and serve as a catalyst to Therapeutic Area Leadership Teams and the Global Product Strategy community, supporting team evolution and adaptation.
  • Monitor Global Product Strategy and Therapeutic Area organizational health and culture.
  • Share critical organizational health issues with the Leadership Team and identify mitigation action plans.
  • Act as a thought partner and drive engagement and change management with Global Product Strategy leaders and the People and Culture function.
  • Lead cross-functional projects to ensure timely and successful delivery of initiatives.
  • Develop and manage project plans, track progress, and identify risks and mitigation strategies.
  • Contribute to the Chief of Staff community through knowledge exchange, collaboration, and sharing standard practices across the organization.
  • Lead the community of Operations Partners for the Therapeutic Areas.
Desired Qualifications
  • Training or an additional degree in business management or project management.
  • Understanding of the pharmaceutical value chain from science through commercial operations.
  • Knowledge of investment decision governance processes and their considerations.
  • Additional languages beyond English.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.